ResearcherNordic Bioscience (Denmark)Active in the last 2 years
M.A. Karsdal
Matched on ORCID iD 0000-0001-5026-8740; OpenAlex author ID A5063475809. Sources: OpenAlex.
Their work
- Papers
- 11 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 15
2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: 2 papers · 2022: 3 papers · 2023: 1 paper · 2024: none · 2025: 2 papers
Papers 11
- BIGH3 is a mediator of TGFβ-Induced collagen formation in fibrosis and pancreatic cancer and a potential therapeutic target. Last author DOI 10.1038/s41598-025-24463-0↗
- Proteolytic degradation of Beta-Ig H3 (βigH3/TGFBI) can be quantified non-invasively in serum and predicts prognosis in patients with advanced pancreatic ducta… Co-author DOI 10.1186/s12885-025-14283-w↗
- High serum levels of the C-propetide of type V collagen (PRO-C5) are prognostic for short overall survival in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.3389/fmolb.2023.1158058↗
- Plasma Kallikrein-Activated TGF-β Is Prognostic for Poor Overall Survival in Patients with Pancreatic Ductal Adenocarcinoma and Associates with Increased Fibro… Co-author DOI 10.3390/biom12091315↗
- Collagen Biomarkers Quantify Fibroblast Activity In Vitro and Predict Survival in Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers14030819↗
- Type XXII Collagen Complements Fibrillar Collagens in the Serological Assessment of Tumor Fibrosis and the Outcome in Pancreatic Cancer. Co-author DOI 10.3390/cells11233763↗
- Noninvasive prognostic biomarker potential of quantifying the propeptides of Type XI collagen alpha-1 chain (PRO-C11) in patients with pancreatic ductal adenoc… Co-author DOI 10.1002/ijc.33551↗
- Blood-based extracellular matrix biomarkers as predictors of survival in patients with metastatic pancreatic ductal adenocarcinoma receiving pegvorhyaluronidas… Co-author DOI 10.1186/s12967-021-02701-z↗
- Clinical value of serum hyaluronan and propeptide of type III collagen in patients with pancreatic cancer. Co-author DOI 10.1002/ijc.32751↗
- Collagen fragments quantified in serum as measures of desmoplasia associate with survival outcome in patients with advanced pancreatic cancer. Co-author DOI 10.1038/s41598-019-56268-3↗
- Extracellular matrix specific protein fingerprints measured in serum can separate pancreatic cancer patients from healthy controls. Co-author DOI 10.1186/1471-2407-13-554↗
Closest collaborators
The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Nicholas Willumsen · 11 shared papers, 2013–2025 · strength 1.52
- Paper Proteolytic degradation of Beta-Ig H3 (βigH3/TGFBI) can be quantified non-invasively in serum and predicts prognosis in… DOI 10.1186/s12885-025-14283-w↗
- Paper BIGH3 is a mediator of TGFβ-Induced collagen formation in fibrosis and pancreatic cancer and a potential therapeutic ta… DOI 10.1038/s41598-025-24463-0↗
- Paper High serum levels of the C-propetide of type V collagen (PRO-C5) are prognostic for short overall survival in patients … DOI 10.3389/fmolb.2023.1158058↗
- Julia Sidenius Johansen · 8 shared papers, 2020–2025 · strength 1.25
- Paper Proteolytic degradation of Beta-Ig H3 (βigH3/TGFBI) can be quantified non-invasively in serum and predicts prognosis in… DOI 10.1186/s12885-025-14283-w↗
- Paper BIGH3 is a mediator of TGFβ-Induced collagen formation in fibrosis and pancreatic cancer and a potential therapeutic ta… DOI 10.1038/s41598-025-24463-0↗
- Paper High serum levels of the C-propetide of type V collagen (PRO-C5) are prognostic for short overall survival in patients … DOI 10.3389/fmolb.2023.1158058↗
- Inna Markovna Chen · 8 shared papers, 2020–2025 · strength 1.25
- Paper Proteolytic degradation of Beta-Ig H3 (βigH3/TGFBI) can be quantified non-invasively in serum and predicts prognosis in… DOI 10.1186/s12885-025-14283-w↗
- Paper BIGH3 is a mediator of TGFβ-Induced collagen formation in fibrosis and pancreatic cancer and a potential therapeutic ta… DOI 10.1038/s41598-025-24463-0↗
- Paper High serum levels of the C-propetide of type V collagen (PRO-C5) are prognostic for short overall survival in patients … DOI 10.3389/fmolb.2023.1158058↗
- Lars Nannestad Jørgensen · 6 shared papers, 2021–2025 · strength 0.98
- Paper Proteolytic degradation of Beta-Ig H3 (βigH3/TGFBI) can be quantified non-invasively in serum and predicts prognosis in… DOI 10.1186/s12885-025-14283-w↗
- Paper BIGH3 is a mediator of TGFβ-Induced collagen formation in fibrosis and pancreatic cancer and a potential therapeutic ta… DOI 10.1038/s41598-025-24463-0↗
- Paper High serum levels of the C-propetide of type V collagen (PRO-C5) are prognostic for short overall survival in patients … DOI 10.3389/fmolb.2023.1158058↗
- Hadi M. H. Diab · 6 shared papers, 2021–2025 · strength 0.98
- Paper Proteolytic degradation of Beta-Ig H3 (βigH3/TGFBI) can be quantified non-invasively in serum and predicts prognosis in… DOI 10.1186/s12885-025-14283-w↗
- Paper BIGH3 is a mediator of TGFβ-Induced collagen formation in fibrosis and pancreatic cancer and a potential therapeutic ta… DOI 10.1038/s41598-025-24463-0↗
- Paper High serum levels of the C-propetide of type V collagen (PRO-C5) are prognostic for short overall survival in patients … DOI 10.3389/fmolb.2023.1158058↗
- Carsten Palnæs Hansen · 6 shared papers, 2020–2025 · strength 0.94
- Paper Proteolytic degradation of Beta-Ig H3 (βigH3/TGFBI) can be quantified non-invasively in serum and predicts prognosis in… DOI 10.1186/s12885-025-14283-w↗
- Paper High serum levels of the C-propetide of type V collagen (PRO-C5) are prognostic for short overall survival in patients … DOI 10.3389/fmolb.2023.1158058↗
- Paper Collagen Biomarkers Quantify Fibroblast Activity In Vitro and Predict Survival in Patients with Pancreatic Ductal Adeno… DOI 10.3390/cancers14030819↗
- Neel Ingemann Nissen · 6 shared papers, 2021–2025 · strength 0.92
- Paper BIGH3 is a mediator of TGFβ-Induced collagen formation in fibrosis and pancreatic cancer and a potential therapeutic ta… DOI 10.1038/s41598-025-24463-0↗
- Paper High serum levels of the C-propetide of type V collagen (PRO-C5) are prognostic for short overall survival in patients … DOI 10.3389/fmolb.2023.1158058↗
- Paper Collagen Biomarkers Quantify Fibroblast Activity In Vitro and Predict Survival in Patients with Pancreatic Ductal Adeno… DOI 10.3390/cancers14030819↗
- Rasmus S. Pedersen · 4 shared papers, 2022–2025 · strength 0.72
- Paper Proteolytic degradation of Beta-Ig H3 (βigH3/TGFBI) can be quantified non-invasively in serum and predicts prognosis in… DOI 10.1186/s12885-025-14283-w↗
- Paper BIGH3 is a mediator of TGFβ-Induced collagen formation in fibrosis and pancreatic cancer and a potential therapeutic ta… DOI 10.1038/s41598-025-24463-0↗
- Paper Collagen Biomarkers Quantify Fibroblast Activity In Vitro and Predict Survival in Patients with Pancreatic Ductal Adeno… DOI 10.3390/cancers14030819↗
- Astrid Zedlitz Johansen · 4 shared papers, 2020–2023 · strength 0.54
- Paper High serum levels of the C-propetide of type V collagen (PRO-C5) are prognostic for short overall survival in patients … DOI 10.3389/fmolb.2023.1158058↗
- Paper Collagen Biomarkers Quantify Fibroblast Activity In Vitro and Predict Survival in Patients with Pancreatic Ductal Adeno… DOI 10.3390/cancers14030819↗
- Paper Noninvasive prognostic biomarker potential of quantifying the propeptides of Type XI collagen alpha-1 chain (PRO-C11) i… DOI 10.1002/ijc.33551↗
- Emilie A. Madsen · 2 shared papers, 2022–2023 · strength 0.31
- Paper High serum levels of the C-propetide of type V collagen (PRO-C5) are prognostic for short overall survival in patients … DOI 10.3389/fmolb.2023.1158058↗
- Paper Type XXII Collagen Complements Fibrillar Collagens in the Serological Assessment of Tumor Fibrosis and the Outcome in P… DOI 10.3390/cells11233763↗
- Song Wang · 1 shared paper, 2021 · strength 0.16
- Per Pfeiffer · 1 shared paper, 2020 · strength 0.10
- Allan Lipton · 1 shared paper, 2019 · strength 0.08
- Nelson S. Yee · 1 shared paper, 2019 · strength 0.08
- Anne‐Christine Bay‐Jensen · 1 shared paper, 2013 · strength 0.04
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.